Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying an experimental drug called odronextamab combined with chemotherapy in patients with Diffuse Large B-cell Lymphoma DLBCL. This includes adults with untreated DLBCL as well as those whose disease has returned or not responded to treatment. The study aims to evaluate the safety, dosing, and effectiveness of odronextamab plus chemotherapy compared to the current standard treatment, rituximab combined with chemotherapy. The study is divided into Part 1A and 1B, which focus on determining safe doses and schedules of odronextamab combined with chemotherapy drugs including cyclophosphamide, doxorubicin, vincristine, and prednisone or prednisolone. Part 2 is a randomized comparison where participants receive either odronextamab plus chemotherapy or rituximab plus chemotherapy. Odronextamab and rituximab are given by intravenous infusion, with rituximab also possibly given subcutaneously. Participants will be monitored for side effects, disease progression, and quality of life over time. Assessments include measuring drug levels in the blood, immune response to the drug, and physical functioning questionnaires. The study will follow participants for up to five years to evaluate progression-free survival and other outcomes. Safety and adverse events will be tracked for up to two years.
Actively Recruiting
Researchers are evaluating the effects of amniotic suspension allograft ASA injections compared to hyaluronic acid HA and saline injections for treating knee osteoarthritis in adults aged 18 to 80. This condition involves joint cartilage damage and inflammation leading to pain and decreased mobility. The study aims to find the best ASA dose and assess its potential to reduce inflammation and improve quality of life compared to existing injection treatments. Participants will be randomly assigned to receive one of four intra-articular knee injections under ultrasound guidance ASA 40 mg, ASA 20 mg, HA, or saline. ASA injections are prepared by diluting AMNIOGEN tissue in saline, while HA and saline are administered as per standard concentrations. The trial is double-blind, ensuring neither participants nor researchers know the assigned treatment. Injections and follow-up occur over a 12-month period. During the study, participants will undergo assessments including pain scales VAS, NRS, knee injury and osteoarthritis outcome scores KOOS, and quality of life evaluations WHOQOL-BREF. Laboratory tests such as complete blood count, C-reactive protein, erythrocyte sedimentation rate, and cytokine levels will be monitored. Imaging with knee ultrasound and X-ray will assess joint status, alongside cartilage protein measurements. Safety and treatment effects will be observed throughout the 12 months of follow-up.
Actively Recruiting
This research aims to collect real-world data on patients with type 2 diabetes, hypertension, heart failure, and chronic kidney disease. It focuses on understanding patient characteristics, disease management, healthcare use, and outcomes across many countries. The study is an observational registry that includes patients seen in regular clinical practice worldwide. Participants are grouped based on their main condition or comorbidities, including type 2 diabetes, hypertension, chronic kidney disease, or heart failure. Data is collected both retrospectively and prospectively using a cloud-based electronic case report form accessible to investigators and a scientific committee. The registry is open to all physicians managing these conditions globally. Participants contribute information about their health status, treatments, and clinical measurements over time. Researchers gather demographic data, disease history, lab tests, imaging, medication use, healthcare visits, and outcomes such as hospitalizations and complications. The study measures many health indicators at baseline and averages over three years to understand care quality and disease progression. Participation can last until the study ends in 2030.
Actively Recruiting
Researchers are evaluating the long-term safety of two drugs, Deucravacitinib and Ustekinumab, in adults with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic treatments. This study is designed to compare these treatments over an extended period, focusing on cardiovascular health and other safety outcomes. The study is sponsored by Bristol-Myers Squibb and is a Phase 3b4 randomized, open-label trial. Participants are randomly assigned to receive either Deucravacitinib or Ustekinumab at specified doses on scheduled days. The study spans up to 5 years, during which participants will be monitored closely for cardiovascular events and other safety outcomes. Treatment adherence and effects will be regularly assessed throughout this long-term safety study. During the study, participants will undergo various evaluations including monitoring for major cardiovascular events such as heart attacks and strokes, other cardiovascular complications, and laboratory assessments including liver function and lipid panels. Researchers will also track serious adverse events and overall mortality up to 60 days after the last dose. This comprehensive monitoring ensures participant safety and gathers essential data on the long-term effects of the treatments over the studys duration, which lasts until January 2031.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of ADI-PEG 20 in adults with Nonalcoholic Steatohepatitis NASH, a liver condition characterized by fat buildup and inflammation. This phase 2A clinical trial compares ADI-PEG 20 with a placebo to understand its impact on liver fat reduction. The study includes careful monitoring of side effects and laboratory tests to ensure participant safety. Participants receive weekly doses of ADI-PEG 20 or placebo via intramuscular injection at 36 mgm2. The trial is randomized and double-blind, meaning neither participants nor researchers know who receives the active drug or placebo. The treatment period lasts 24 weeks, during which liver fat changes are assessed using MRI-PDFF imaging. An independent committee oversees safety by reviewing adverse events and clinical data. During the study, participants undergo regular health evaluations including vital signs, body weight checks, ECGs, and blood tests. Liver fat levels are measured at the start and at week 24 to assess treatment effects. Safety is monitored continuously through adverse event reporting and laboratory tests. The total participation time spans 24 weeks, with ongoing review of safety and efficacy outcomes throughout.
Actively Recruiting
Researchers are evaluating whether lymphatic surgery offers better quality of life compared to conservative treatment for patients with chronic breast cancer-related lymphedema. This study aims to provide solid scientific evidence on the superiority of surgical techniques over standard conservative therapy, addressing the physical, psychological, and financial burdens faced by affected patients. It is a pragmatic, randomized, multicenter trial designed to compare these treatments in real-world conditions. Participants are assigned to one of two groups the surgical group receiving advanced microsurgical procedures such as lymphovenous anastomosis and vascularized lymph node transfer, possibly combined with liposuction, or the conservative therapy group receiving complex physical decongestion therapy CDT. CDT includes manual lymphatic drainage, compression with bandages or garments, physical exercises, and skin care in two phases an intensive phase and a maintenance phase. Both treatments are delivered according to usual care practices with flexibility for the treating clinicians. Throughout the study, participants complete quality of life questionnaires at baseline and 15 months after randomization, with long-term assessments continuing up to 10 years. Researchers will monitor pain, surgical complications, lymphangitic events, arm volume, frequency of lymphatic drainage, patient burden, and economic factors. Safety and adverse events are assessed for up to two years. The study is sponsored by the University Hospital Basel, Switzerland, and participants are followed for many years to understand the lasting impacts of each treatment approach.